a Feasibility Study of iHD-SRT for BM

NCT06231186 | Recruiting

• 1 other identifier: 2024（006）
• Study Type: interventional
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

Brain metastasis is the most challenging disease in the field of tumor treatment, with a median overall survival of only 1-2 months for untreated patients. Stereotactic radiotherapy (SRT) has the advantages of precise positioning, relatively concentrated dosage, shorter course, and lower toxicity. Several studies could effectively protect cognitive function and achieve better tumor control rate. Currently, it has gradually replaced WBRT as standard local treatment choice for brain metastases. SRT includes Stereotactic Radiosurgery (SRS) and Fractional Stereotactic Radiotherapy (fSRT). With the continuous updating of domestic radiation therapy equipment, the use of high-resolution multi leaf gratings enables the accuracy of fSRT based on linear accelerators to reach 0.5mm or even lower levels, and has gradually become one of the main choices for local treatment of a limited number of patients with brain metastases. However, there is currently no prospective randomized controlled study data analyzing the clinical benefits of different segmentation and dosages of SRT. In retrospective data comparing different segmentation schemes, researchers found that higher BED was associated with better local control. However, the ASTRO guidelines recommend relatively conservative doses for SRT of brain metastases, especially as the lesion volume increases, and the recommended dose of BED10 for SRT was only 48 Gy (30 Gy/5 Fx). This is based on the consideration that higher radiation exposure will bring a higher risk of radiation-induced brain necrosis. However, with the continuous updates of SRT treatment equipment and technology, existing technologies can achieve higher dose coverage for more brain metastases while meeting the normal tissue limit. Therefore, this study conducted a prospective intervention study to explore the feasibility and safety of optimizing SRT dosage based on normal tissue tolerance for the treatment of brain metastases, in order to further improve the therapeutic effect of intracranial lesions with brain metastases. This study is designed as a single arm open prospective study, assuming that under this treatment regimen, the proportion of patients with lesion prescription dose BED10\>50 Gy is 90%, and the incidence of radiation-induced brain necrosis within 1 year is 8.5%. The planned enrollment period is 2 years and follow-up period is 1 year. A total of 35 people need to be enrolled.

Conditions

Brain Metastases, Adult; Stereotactic Radiotherapy

Outcome Measures

Primary Outcomes (2)

• proportion of patients receiving BED 10 >50 Gy

  proportion of patients receiving BED 10 \>50 Gy

  through treatment completion, an average of 1 month

• the incidence of radiation-induced brain necrosis

  The incidence of radiation-induced brain necrosis

  1 year

Study Arms (1)

iHD-SRT

EXPERIMENTAL

isotoxic high dose SRT

Radiation: iHD-SRT

Interventions

iHD-SRT RADIATION

received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits

iHD-SRT

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to understand and willingness to participate the research and sign the consent form
• ECOG PS 0-2
• The primary or metastatic lesion was confirmed by pathological histology as a malignant tumor
• Head MRI diagnosis of brain metastasis with measurable lesions and technically feasible SRT (no more than 15 in number and 20cc in volume)
• Estimated survival time ≥ 3 months

You may not qualify if:

• Diffuse brain metastases, or combined with meningeal metastases, or technically difficult to perform SRT
• With severe internal medicine complications or absolute contraindications for radiotherapy
• other sufficient reasons to be unqualified, such as potential non-compliance with the clinical protocol, etc

Sponsors & Collaborators

• Ruijin Hospital: lead

Study Sites (1)

Ruijin Hospital

Shanghai, Shanghai Municipality, 200000, China

RECRUITING

MeSH Terms

Conditions

Brain Neoplasms

Condition Hierarchy (Ancestors)

Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Jiayi Chen

  Ruijin Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Dan Ou, MD

CONTACT

8618801970632; od12341@rjh.com.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof

Study Record Dates

• First Submitted: January 19, 2024
• First Posted: January 30, 2024
• Study Start: March 15, 2024
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: April 10, 2024

Record last verified: 2024-04

Locations

CN (1)